JP2022513350A5 - - Google Patents
Info
- Publication number
- JP2022513350A5 JP2022513350A5 JP2021545279A JP2021545279A JP2022513350A5 JP 2022513350 A5 JP2022513350 A5 JP 2022513350A5 JP 2021545279 A JP2021545279 A JP 2021545279A JP 2021545279 A JP2021545279 A JP 2021545279A JP 2022513350 A5 JP2022513350 A5 JP 2022513350A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024030048A JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745464P | 2018-10-15 | 2018-10-15 | |
| US62/745,464 | 2018-10-15 | ||
| US201962802091P | 2019-02-06 | 2019-02-06 | |
| US62/802,091 | 2019-02-06 | ||
| US201962854494P | 2019-05-30 | 2019-05-30 | |
| US62/854,494 | 2019-05-30 | ||
| PCT/US2019/056210 WO2020081497A1 (en) | 2018-10-15 | 2019-10-15 | Combination therapy for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030048A Division JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513350A JP2022513350A (ja) | 2022-02-07 |
| JP2022513350A5 true JP2022513350A5 (https=) | 2022-10-20 |
| JP7448552B2 JP7448552B2 (ja) | 2024-03-12 |
Family
ID=68393113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545279A Active JP7448552B2 (ja) | 2018-10-15 | 2019-10-15 | がんの併用療法 |
| JP2024030048A Pending JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030048A Pending JP2024059913A (ja) | 2018-10-15 | 2024-02-29 | がんの併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210332137A1 (https=) |
| EP (1) | EP3867274A1 (https=) |
| JP (2) | JP7448552B2 (https=) |
| KR (1) | KR20210076025A (https=) |
| CN (1) | CN113166242B (https=) |
| AU (1) | AU2019361923A1 (https=) |
| BR (1) | BR112021007134A2 (https=) |
| CA (1) | CA3114955A1 (https=) |
| IL (1) | IL282093A (https=) |
| MA (1) | MA53911A (https=) |
| MX (1) | MX2021004226A (https=) |
| SG (1) | SG11202103153VA (https=) |
| TW (1) | TWI835885B (https=) |
| WO (1) | WO2020081497A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| CN117980332A (zh) * | 2020-08-18 | 2024-05-03 | Abl生物公司 | 抗b7-h4/抗4-1bb双特异性抗体及其应用 |
| MX2023008000A (es) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics Inc | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. |
| GB202402046D0 (en) * | 2024-02-14 | 2024-03-27 | Bivictrix Ltd | Therapeutic antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| ES2252261T3 (es) | 2000-06-28 | 2006-05-16 | Glycofi, Inc. | Metodos para producir glicoproteinas modificadas. |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CN101613705A (zh) | 2002-03-19 | 2009-12-30 | 国际植物研究所 | 在植物中优化聚糖生成 |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| BRPI0611445A2 (pt) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| JP2009526520A (ja) | 2006-01-17 | 2009-07-23 | バイオレックス セラピュティックス インク | 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法 |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| BR122017025062B8 (pt) * | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| US9562099B2 (en) * | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US10626176B2 (en) * | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| CN110300599B (zh) * | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| DK3551660T5 (da) * | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| US11306144B2 (en) * | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| CA3091161A1 (en) * | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody dosing regimens |
-
2019
- 2019-10-15 KR KR1020217012944A patent/KR20210076025A/ko active Pending
- 2019-10-15 MA MA053911A patent/MA53911A/fr unknown
- 2019-10-15 MX MX2021004226A patent/MX2021004226A/es unknown
- 2019-10-15 EP EP19795757.4A patent/EP3867274A1/en active Pending
- 2019-10-15 JP JP2021545279A patent/JP7448552B2/ja active Active
- 2019-10-15 CN CN201980071763.6A patent/CN113166242B/zh active Active
- 2019-10-15 WO PCT/US2019/056210 patent/WO2020081497A1/en not_active Ceased
- 2019-10-15 BR BR112021007134-2A patent/BR112021007134A2/pt unknown
- 2019-10-15 CA CA3114955A patent/CA3114955A1/en active Pending
- 2019-10-15 SG SG11202103153VA patent/SG11202103153VA/en unknown
- 2019-10-15 TW TW108137035A patent/TWI835885B/zh active
- 2019-10-15 AU AU2019361923A patent/AU2019361923A1/en active Pending
-
2021
- 2021-04-06 IL IL282093A patent/IL282093A/en unknown
- 2021-04-07 US US17/224,865 patent/US20210332137A1/en active Pending
-
2024
- 2024-02-29 JP JP2024030048A patent/JP2024059913A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513350A5 (https=) | ||
| JP2021513997A5 (https=) | ||
| KR102757960B1 (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| JP2018538274A5 (https=) | ||
| JP2017514461A5 (https=) | ||
| JP2020503273A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2018503365A5 (https=) | ||
| JP2020515247A5 (https=) | ||
| JP2017500028A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| JP2017501167A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2017500057A5 (https=) | ||
| JP2017534577A5 (https=) | ||
| JP2022512750A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JP2021512107A5 (https=) | ||
| JP2020528936A5 (https=) | ||
| CN112351794A (zh) | 用于尿路上皮癌的免疫治疗方法 | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2024535930A5 (https=) | ||
| JP2023545521A5 (https=) |